Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Gastric Cancer Management and Outcomes, Inflammatory Biomarkers in Disease Prognosis, Metastasis and carcinoma case studies, and Gastrointestinal Tumor Research and Treatment.
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial
ASAP1 protein macromolecule promotes the growth and development of gastric cancer cells and the remodeling of F-actin cytoskeleton: Expression of VEGF and HIF-1 α proteins
OP0302 RUZINURAD FOR HYPERURICEMIA ASSOCIATED WITH PRIMARY GOUT: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PHASE 3 STUDY
Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial
Integrating Machine Learning and the SHapley Additive exPlanations (SHAP) Framework to Predict Lymph Node Metastasis in Gastric Cancer Patients Based on Inflammation Indices and Peripheral Lymphocyte Subpopulations
Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor
Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor
Clinical significance of systemic inflammation response index and platelet–lymphocyte ratio in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer
A prognostic marker LTBP1 is associated with epithelial mesenchymal transition and can promote the progression of gastric cancer
Suppression of gastric cancer cell proliferation by miR-494-3p inhibitor-loaded engineered exosomes
Machine learning algorithms able to predict the prognosis of gastric cancer patients treated with immune checkpoint inhibitors
Prognostic Value of Fibrinogen to Prealbumin Ratio (FPR) in Resectable Gastric Cancer
Machine learning methods predict recurrence of pN3b gastric cancer after radical resection
Development of a tongue image-based machine learning tool for the diagnosis of gastric cancer: a prospective multicentre clinical cohort study
LBA78 Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy: An updated analysis of RESOLVE trial
Cancer‐associated fibroblast expression of glutamine fructose‐6‐phosphate aminotransferase 2 (<scp>GFPT2</scp>) is a prognostic marker in gastric cancer
Nomogram Based on Preoperative Fibrinogen and Systemic Immune-Inflammation Index Predicting Recurrence and Prognosis of Patients with Borrmann Type III Advanced Gastric Cancer
Normalization weighted combination scores re-evaluate TNM staging of gastric cancer: a retrospective cohort study based on a multicenter database
Efficacy of Lymph Node Location-Number Hybrid Staging System on the Prognosis of Gastric Cancer Patients
Combined with prognostic nutritional index and IgM for predicting the clinical outcomes of gastric cancer patients who received surgery
Development and Validation of Tumor Marker Indices in Advanced Gastric Cancer Patients
Lymphocyte subset is more suitable than systemic inflammatory response biomarker and immunoglobulin in constructing prognostic nomogram model for advanced gastric cancer
Laparoscopic versus open gastrectomy for gastric cancer: A systematic review and meta-analysis of randomized controlled trials
Comprehensive Characterization of Tumor Purity and Its Clinical Implications in Gastric Cancer
Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
Prognostic nutritional index for predicting the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors
The prognostic marker elastin correlates with <scp>epithelial–mesenchymal</scp> transition and <scp>vimentin‐positive</scp> fibroblasts in gastric cancer
Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer
Prognostic importance of the preoperative New‐Naples prognostic score for patients with gastric cancer
The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors